About Akero Therapeutics
Akero Therapeutics is a company based in San Francisco (United States) founded in 2017 was acquired by Novo Nordisk in October 2025.. Akero Therapeutics has raised $135 million across 4 funding rounds from investors including Pfizer, Novo Nordisk and Janus Henderson Investors. The company has 63 employees as of December 31, 2024. Akero Therapeutics offers products and services including Efruxifermin (EFX). Akero Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
- Headquarter San Francisco, United States
- Employees 63 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Akero Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-252.06 M-66.09as on Dec 31, 2024
-
EBITDA
$-285.4 M-65.13as on Dec 31, 2024
-
Total Equity Funding
$135 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jun 16, 2022
-
Investors
Pfizer
& 11 more
-
Employee Count
63
as on Dec 31, 2024
-
Acquired by
Novo Nordisk
(Oct 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Akero Therapeutics
Akero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AKRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Akero Therapeutics
Akero Therapeutics offers a comprehensive portfolio of products and services, including Efruxifermin (EFX). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational treatment for metabolic dysfunction-associated steatohepatitis.
Unlock access to complete
Unlock access to complete
Funding Insights of Akero Therapeutics
Akero Therapeutics has successfully raised a total of $135M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(22 Jun 2018)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Post-IPO - Akero Therapeutics | Valuation |
investors |
|
| Jul, 2020 | Amount | Post-IPO - Akero Therapeutics | Valuation |
investors |
|
| Dec, 2018 | Amount | Series B - Akero Therapeutics | Valuation | Janus Henderson Investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Akero Therapeutics
Akero Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novo Nordisk and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare startups are funded by this corporate-backed venture capital entity.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Akero Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Akero Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Akero Therapeutics Comparisons
Competitors of Akero Therapeutics
Akero Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Akero Therapeutics
Frequently Asked Questions about Akero Therapeutics
When was Akero Therapeutics founded?
Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Akero Therapeutics located?
Akero Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Akero Therapeutics a funded company?
Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date. The company's 1st funding round was a Series B of $70M, raised on Jun 22, 2018.
How many employees does Akero Therapeutics have?
As of Dec 31, 2024, the latest employee count at Akero Therapeutics is 63.
What does Akero Therapeutics do?
Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.
Who are the top competitors of Akero Therapeutics?
Akero Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does Akero Therapeutics offer?
Akero Therapeutics offers Efruxifermin (EFX).
Is Akero Therapeutics publicly traded?
Yes, Akero Therapeutics is publicly traded on NASDAQ under the ticker symbol AKRO.
Who are Akero Therapeutics's investors?
Akero Therapeutics has 12 investors. Key investors include Pfizer, Novo Nordisk, Janus Henderson Investors, Atlas Venture, and LifeSci Venture Partners.
What is Akero Therapeutics's ticker symbol?
The ticker symbol of Akero Therapeutics is AKRO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.